BioCryst Pharmaceuticals Inc. (BCRX)

3.67
0.07 1.81
NASDAQ : Health Technology
Prev Close 3.60
Open 3.66
Day Low/High 3.57 / 3.86
52 Wk Low/High 2.80 / 9.95
Volume 890.47K
Avg Volume 2.05M
Exchange NASDAQ
Shares Outstanding 110.31M
Market Cap 397.13M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
BioCryst (BCRX) Stock Downgraded at Jefferies

BioCryst (BCRX) Stock Downgraded at Jefferies

Jefferies downgraded BioCryst (BCRX) stock and slashed its price target after the company announced disappointing trial results yesterday.

BioCryst (BCRX) Stock Plummets on Disappointing Trial Results

BioCryst (BCRX) Stock Plummets on Disappointing Trial Results

BioCryst (BCRX) stock is sinking on heavy trading volume on Monday after the company reported disappointing trial results for its treatment for angioedema attacks.

Investors Flee Risky Equities for Save-Haven Gold

Investors Flee Risky Equities for Save-Haven Gold

Stocks continue their sell off mid-afternoon Monday with investors finding little reason to jump back into equities as the risks over oil and earnings persisted.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By The Board Of BioCryst Pharmaceuticals, Inc. -- BCRX

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By The Board Of BioCryst Pharmaceuticals, Inc. -- BCRX

Levi & Korsinsky announces it has commenced an investigation of BioCryst Pharmaceuticals, Inc.

Midday Report: Chesapeake Energy Tanks; Stocks Extend Selloff

Midday Report: Chesapeake Energy Tanks; Stocks Extend Selloff

U.S. stocks picked up where they left off last week, extending a sharp selloff on Monday on worries over oil and disappointing earnings.

Stocks at Session Lows as Investors Find No Reason to Buy

Stocks at Session Lows as Investors Find No Reason to Buy

Stocks fall to session lows on Monday morning as investors find little reason to buy with no good news to turn around sentiment since Friday's big selloff.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies are scooping up shares of their own stock lately.

Biocryst Pharmaceuticals (BCRX) Weak On High Volume Today

Biocryst Pharmaceuticals (BCRX) Weak On High Volume Today

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a weak on high relative volume candidate

Interesting BCRX Put And Call Options For September 16th

Interesting BCRX Put And Call Options For September 16th

Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading this week, for the September 16th expiration.

Short Interest In BioCryst Pharmaceuticals Declines 11.3%

Short Interest In BioCryst Pharmaceuticals Declines 11.3%

The most recent short interest data has been released by the NASDAQ for the 12/31/2015 settlement date, which shows a 1,010,643 share decrease in total short interest for BioCryst Pharmaceuticals, Inc. , to 7,958,952, a decrease of 11.27% since 12/15/2015.

Biocryst Pharmaceuticals (BCRX) Weak On High Volume Today

Biocryst Pharmaceuticals (BCRX) Weak On High Volume Today

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a weak on high relative volume candidate

Strong On High Volume: Biocryst Pharmaceuticals (BCRX)

Strong On High Volume: Biocryst Pharmaceuticals (BCRX)

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a strong on high relative volume candidate

Insider Trading Alert - MAIN, TRC And BCRX Traded By Insiders

Insider Trading Alert - MAIN, TRC And BCRX Traded By Insiders

Stocks with insider trader activity include MAIN, TRC and BCRX

Trade-Ideas: Biocryst Pharmaceuticals (BCRX) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: Biocryst Pharmaceuticals (BCRX) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a "dead cat bounce" (down big yesterday but up big today) candidate

BioCryst Pharmaceuticals (BCRX) Stock Drops Despite Positive Drug Trial Results

BioCryst Pharmaceuticals (BCRX) Stock Drops Despite Positive Drug Trial Results

BioCryst Pharmaceuticals (BCRX) shares are down over 15% in afternoon trading despite positive phase 1 test results after the company said that some patients experienced adverse reactions.

Biocryst Pharmaceuticals (BCRX) Stock: Weak On High Volume Today

Biocryst Pharmaceuticals (BCRX) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a weak on high relative volume candidate

Trade-Ideas: Biocryst Pharmaceuticals (BCRX) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Biocryst Pharmaceuticals (BCRX) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a strong on high relative volume candidate

3 Stocks Pushing The Health Care Sector Lower

3 Stocks Pushing The Health Care Sector Lower

TheStreet highlights 3 stocks pushing the Health Care sector lower today.

Market News: American Express, BioCryst Pharmaceuticals, CF Industries

Market News: American Express, BioCryst Pharmaceuticals, CF Industries

The stock markets in the United States ended the trading down as investors resumed selling their stockholdings in biotechnology and commodity companies. Sign up for our free newsletter Yesterday, the...

BioCryst Pharmaceuticals Becomes Oversold (BCRX)

BioCryst Pharmaceuticals Becomes Oversold (BCRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TheStreet Quant Rating: D- (Sell)